-

SHAREHOLDER ALERT: Robbins LLP Announces That MoneyGram International, Inc. (MGI) is Being Sued for Misleading Shareholders

SAN DIEGO & DALLAS--(BUSINESS WIRE)--Shareholder rights law firm Robbins LLP announces that a purchaser of MoneyGram International, Inc. (NASDAQ: MGI) filed a class action complaint against the Company and its officers and directors for alleged violations of the Securities Exchange Act of 1934 between June 17 2019 and February 22, 2021.

If you suffered a loss due to MoneyGram International Inc.'s misconduct, click here.

MoneyGram International, Inc. (MGI) Misled Investors About

According to the complaint, on June 17, 2019, MoneyGram announced it was entering into a strategic partnership with Ripple Labs, Inc. Ripple is a blockchain technology company and the developer of cryptocurrency XRP. As part of the partnership, Ripple agreed to invest up to $50 million in MoneyGram stock. On this news, the price of MoneyGram stock increased over 150%. Throughout the relevant period, MoneyGram touted the partnership, stating that it will reduce our working capital needs and generate additional earnings and cash flows." The Company also made statements regarding the strong contribution that market development fees received from Ripple made to MoneyGram's financial results.

On December 22, 2020, the Securities and Exchange Commission ("SEC") filed a lawsuit against Ripple, alleging that Ripple's cryptocurrency XRP is an unregistered security in violation of the securities laws. With regard to MoneyGram's involvement, the SEC complaint explains that the major non-investment use of the XRP cryptocurrency is transferring money on Ripple's ODL platform and that in order to convince anyone to use ODL to transfer money, Ripple had to make a $50 million equity investment and pay sufficient financial compensation to an entity referred to as the "Money Transmitter," i.e., MoneyGram. The SEC complaint further explains how MoneyGram took park in the sale of unregistered XRP securities on the open market.

On February 22, 2021, MoneyGram filed its annual report on Form 10-K for the year ended December 31, 2020, stating: "MoneyGram ceased transacting with Ripple under the commercial agreement in early December 2020 and has not resumed trading. It is possible that MoneyGram will not resume transacting with Ripple … and will be unable to receive the related market development fees in 2021 and beyond." On this news, MoneyGram stock fell 33.2%, from a closing price of $10.87 on February 19, 2021, to $7.26 on February 23, 2021.

If you purchased shares of MoneyGram International Inc. (MGI) between June 17, 2019 and February 22, 2021, you have until April 30, 2021, to ask the court to appoint you lead plaintiff for the class.

Contact us to learn more:
Lauren Levi
(800) 350-6003
llevi@robbinsllp.com
Shareholder Information Form

Robbins LLP is a nationally recognized leader in shareholder rights law. To be notified if a class action against MoneyGram International, Inc. settles or to receive free alerts about companies engaged in wrongdoing, sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.

Contacts

Lauren Levi
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
llevi@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

More News From Robbins LLP

Robbins LLP Urges BBNX Stockholders Who Lost Money Investing in Beta Bionics, Inc. to Contact the Firm for Information About Leading the Class Action

SAN DIEGO--(BUSINESS WIRE)--Shareholder rights law firm Robbins LLP reminds investors that a class action was filed on behalf of all persons and entities who purchased or otherwise acquired Beta Bionics, Inc. (NASDAQ: BBNX) common stock between July 30, 2025 and February 24, 2026, inclusive (the "Class Period"). Beta Bionics is a commercial-stage medical device company that offers an automated insulin delivery system for the treatment of diabetes, known as the iLet Bionic Pancreas insulin pump (...

Robbins LLP Urges HIMS Stockholders Who Lost Money Investing in Hims & Hers Health, Inc. to Contact the Firm for Information About Leading the Class Action

SAN DIEGO--(BUSINESS WIRE)--Shareholder rights law firm Robbins LLP reminds investors that a class action was filed on behalf of all persons and entities who purchased or otherwise acquired Hims & Hers Health, Inc. (NYSE: HIMS) securities between August 4, 2025 and July 29, 2026, inclusive (the "Class Period"). Hims operates a health and wellness platform that connects consumers to licensed healthcare professionals.The complaint alleges that Hims & Hers shared customers' protected health...

Robbins LLP Urges UNCY Stockholders Who Lost Money Investing in Unicycive Therapeutics, Inc. to Contact the Firm for Information About Leading the Class Action

SAN DIEGO--(BUSINESS WIRE)--Shareholder rights law firm Robbins LLP reminds investors that a class action was filed on behalf of persons and entities who purchased or otherwise acquired Unicycive Therapeutics, Inc. (NASDAQ: UNCY) securities between December 29, 2025 and June 29, 2026. Unicycive is a clinical-stage biotechnology company that identifies, develops, and commercializes therapies for the treatment of kidney diseases.The complaint alleges that Unicycive failed to properly inspect its t...
Back to Newsroom